Does Humana Cover Enclomiphene Citrate?

Humana's Current Formulary Position on Enclomiphene Citrate

Enclomiphene citrate does not appear on Humana's published commercial or Medicare Advantage formularies as of early 2026. The drug remains without standalone FDA approval for the treatment of secondary hypogonadism, which places it in a coverage gray zone for most insurers [1]. Humana's pharmacy benefit management follows CMS National Coverage Determination guidelines for its MA plans, and off-label drugs without a compendia-supported indication face automatic non-coverage under Part D rules [2].

On the commercial side, Humana plan documents classify non-formulary drugs under Tier 4 or exclude them entirely. Enclomiphene obtained through a compounding pharmacy adds another layer of difficulty: Humana's commercial plans generally do not cover compounded medications unless the prescriber demonstrates that no FDA-approved equivalent exists [3]. Since clomiphene citrate (a racemic mixture of enclomiphene and zuclomiphene) is FDA-approved and available as a generic, Humana pharmacy reviewers frequently point to it as a covered alternative.

The practical result is that most Humana members pay out of pocket. Compounded enclomiphene costs between $30 and $90 per month depending on the pharmacy, a price point that is lower than many specialty drugs but still meaningful for patients on fixed incomes [4].

Why Enclomiphene Citrate Gets Denied: The Off-Label Problem

The core issue is regulatory. Enclomiphene citrate was studied in Phase III trials for secondary hypogonadism but has not received FDA approval as a standalone agent [5]. The FDA approved clomiphene citrate decades ago for ovulatory dysfunction in women, and its off-label use in men for testosterone restoration, while clinically common, lacks a formal indication [6].

Humana applies its standard medical necessity criteria when evaluating off-label drug requests. For a drug to qualify, the indication must appear in at least one of the recognized compendia (AHFS Drug Information, DrugDex, or the NCCN guidelines for oncology drugs). Secondary hypogonadism treatment with enclomiphene does not currently meet that threshold [7].

This matters because even when a prescriber submits compelling clinical evidence, the initial formulary screen rejects the claim automatically. The denial letter will typically cite "not medically necessary" or "non-formulary drug," which is a formulary-level exclusion rather than a clinical judgment [8].

Prior Authorization: What Humana Requires

Submitting a prior authorization for enclomiphene citrate on a Humana commercial plan requires specific clinical documentation. The request has a better chance of approval when it includes the following.

Laboratory evidence of hypogonadism. Two morning total testosterone levels below 300 ng/dL, drawn on separate days, with concurrent LH and FSH levels. The Endocrine Society's 2018 guideline defines the diagnostic threshold for hypogonadism and recommends confirmatory testing before treatment [9].

Documentation of treatment failure or contraindication. Humana reviewers expect evidence that the patient tried clomiphene citrate (the racemic form) and either experienced intolerable side effects or failed to reach target testosterone levels. Alternatively, a documented contraindication to exogenous testosterone (such as active fertility goals or a history of erythrocytosis with testosterone therapy) strengthens the request [10].

Clinical rationale for enclomiphene over clomiphene. The pharmacologic argument rests on the trans-isomer's selective estrogen receptor modulation without the anti-estrogenic effects attributed to zuclomiphene. Kim et al. (2016) demonstrated in a 3-month randomized trial that enclomiphene 25 mg daily raised total testosterone from a mean of 228 ng/dL to 454 ng/dL while maintaining sperm concentration, compared to testosterone gel which suppressed spermatogenesis [1]. Citing this data directly in the prior authorization letter helps frame the medical necessity argument.

Prescriber credentials. A letter from an endocrinologist or urologist carries more weight than one from a primary care provider in Humana's peer review process [11].

Response times vary. Humana's commercial plans typically return a prior authorization decision within 5 to 10 business days for non-urgent requests. Expedited review, available when the patient faces clinical harm from delay, takes 24 to 72 hours [12].

Step Therapy Requirements on Humana Plans

Most Humana commercial plans enforce step therapy for testosterone-related treatments. The standard protocol requires that patients try at least one first-line therapy before the plan will consider covering a non-formulary alternative.

For hypogonadism, the first-line step is typically generic clomiphene citrate 25 to 50 mg daily. This is consistent with the American Urological Association's 2018 guideline, which lists clomiphene as an off-label but evidence-supported option for men seeking testosterone restoration without fertility compromise [13]. Humana considers a minimum 90-day trial at therapeutic doses as adequate step therapy documentation.

Some plans also require a trial of topical testosterone (such as AndroGel or generic testosterone cypionate injections) as an alternative step. This creates a paradox for patients who need enclomiphene specifically because they want to avoid exogenous testosterone's suppression of the hypothalamic-pituitary-gonadal axis [14].

If a prescriber documents that exogenous testosterone is contraindicated (for example, in a man actively trying to conceive), Humana may grant a step therapy exception. The exception request should include semen analysis results and a clear statement of fertility intent [15].

Medicare Advantage Plans: A Harder Path

Humana's Medicare Advantage plans present a more difficult coverage situation than commercial plans. CMS rules prohibit Part D coverage of drugs used for weight loss, cosmetic purposes, or off-label indications without compendia support [2]. Since enclomiphene's primary studied indication (secondary hypogonadism) is off-label, MA plans almost uniformly deny coverage.

The denial rate on MA plans approaches 90% for initial requests based on available payer trend data. Even with strong clinical documentation, the CMS coverage framework leaves little room for formulary exceptions on non-compendia drugs [16].

Part B coverage is not an alternative here. Enclomiphene is an oral medication, and Part B covers only injectable or infused drugs administered in a clinical setting. There is no J-code or HCPCS code assigned to enclomiphene citrate [17].

For MA beneficiaries who receive a denial, the appeal route differs from commercial plans and includes the MAXIMUS Federal Services external review process after exhausting Humana's internal levels [18].

How to Appeal a Humana Denial of Enclomiphene Citrate

A structured appeal significantly improves the odds of overturning a denial on commercial Humana plans. The appeal process follows a defined sequence.

Level 1: Internal appeal. Filed within 180 days of the denial. The appeal should include a letter of medical necessity from the prescribing physician, relevant lab results (testosterone, LH, FSH, estradiol), documentation of prior treatment failures, and published clinical evidence supporting enclomiphene use. The Kim et al. BJU International study [1] and Wiehle et al.'s Phase III data showing sustained testosterone elevation over 12 months are the strongest references [5].

Level 2: External review. If the internal appeal is denied, Humana members can request an independent external review through the state's insurance department. This review is conducted by a physician who is not affiliated with Humana. External reviewers tend to weigh peer-reviewed evidence more heavily than formulary policy [19].

For Medicare Advantage members: After the internal appeal, the case goes to an Independent Review Entity contracted through CMS, and the final administrative appeal level is the Medicare Appeals Council [18].

Key tips for a successful appeal: include a peer-to-peer review request with the initial appeal, which allows the prescriber to speak directly with Humana's medical director. Reference the Endocrine Society's guideline on male hypogonadism, which acknowledges selective estrogen receptor modulators as a treatment option [9]. Quantify the clinical benefit with pre- and post-treatment testosterone levels if the patient has already started enclomiphene through cash pay.

Alternatives If Humana Will Not Cover Enclomiphene

When coverage is denied and the appeal fails, several options remain.

Cash-pay through compounding pharmacies. Enclomiphene citrate is available from compounding pharmacies at $30 to $90 per month. Prices vary by pharmacy and dosage. GoodRx and similar discount platforms do not typically list compounded drugs, so patients should call compounding pharmacies directly for pricing [4].

Clomiphene citrate (racemic). Generic clomiphene 25 mg tablets cost $10 to $30 per month and are covered by most Humana plans. While the zuclomiphene isomer may contribute to estrogenic side effects (visual disturbances, mood changes), many men tolerate the racemic form well. A 2015 meta-analysis of clomiphene use in male hypogonadism reported a mean testosterone increase of 292 ng/dL across pooled studies [20].

Telehealth hormone clinics. Some direct-to-patient telehealth platforms prescribe enclomiphene and bundle the medication cost with the consultation fee. These bypass insurance entirely. Patients should verify that the prescribing provider holds an active medical license in their state and that the pharmacy sources USP-grade enclomiphene [21].

Testosterone therapy with fertility preservation. For men not actively trying to conceive, testosterone cypionate injections (100 to 200 mg every 1 to 2 weeks) are covered by most Humana plans at generic pricing. The 2018 AUA guideline recommends concurrent hCG (human chorionic gonadotropin) at 500 IU three times per week if fertility preservation is desired during testosterone therapy [13].

Enclomiphene Citrate's Clinical Evidence for Hypogonadism

The clinical data supporting enclomiphene use in male hypogonadism comes from several trials, though the drug has not cleared the FDA approval threshold.

Kim et al. (2016) randomized 125 men with secondary hypogonadism to enclomiphene 25 mg, testosterone gel 1.62%, or placebo for 16 weeks. Enclomiphene raised mean total testosterone from 228 to 454 ng/dL, while testosterone gel raised it from 232 to 412 ng/dL. The difference was not significant between active arms, but enclomiphene preserved sperm concentration (62.8 million/mL vs. 23.8 million/mL with testosterone gel, P<0.001) [1].

Wiehle et al. (2014) published Phase III results showing that enclomiphene 12.5 mg and 25 mg daily maintained testosterone levels above 300 ng/dL in over 80% of treated men over 6 months [5]. The drug also maintained or increased LH and FSH, confirming its mechanism as a hypothalamic estrogen receptor antagonist rather than a gonadal suppressor [22].

The Endocrine Society's 2018 Clinical Practice Guideline on testosterone therapy acknowledges SERMs as a therapeutic option for men with functional hypogonadism, particularly when fertility is a concern, though it notes the evidence base is smaller than for direct testosterone replacement [9].

These data points are the foundation of any prior authorization or appeal argument. Prescribers should cite specific outcomes (testosterone levels, sperm counts, P-values) rather than general statements about efficacy when communicating with Humana reviewers.

What to Expect in 2026 and Beyond

The coverage picture may shift if enclomiphene citrate receives FDA approval as a standalone product for hypogonadism. As of May 2026, no NDA (New Drug Application) approval has been granted, though the compound remains under active investigation by at least one pharmaceutical company [23]. FDA approval would trigger formulary review at Humana and other major payers, likely placing enclomiphene on Tier 2 or Tier 3 as a branded specialty drug.

Until then, Humana members seeking enclomiphene coverage should work with their prescriber to submit a detailed prior authorization, exhaust the appeal process if denied, and consider cash-pay compounding as a practical alternative at $30 to $90 per month.